Deals

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension
CVDHigh blood pressure

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and Jiangsu Vanguard Pharmaceutical Co., Ltd. entered into a co-development agreement for the ABA001 project, a small interfering RNA (siRNA) drug targeting…

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Chugai Pharmaceutical and InxMed Sign Worldwide License Agreement for SPYK04 – RAF‑MEK Molecular Glue Candidate for Solid Tumors

Chugai Pharmaceutical and InxMed Sign Worldwide License Agreement for SPYK04 – RAF‑MEK Molecular Glue Candidate for Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Brii BiosciencesCancer

Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal

Akeso BiopharmaDawnrays Pharmaceutical

Akeso Biopharma to Acquire 35% Stake in AD Pharmaceuticals for RMB 267 Million

I-MAB BiopharmaNASDAQ: IMAB

I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million

AbbVieAuto-immune

AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research

Show More